Annovis Bio has received approval to open additional European clinical trial sites for the Phase III study of buntanetap to treat Parkinson’s disease (PD).

The approval will add 48 additional clinical trial sites in five European Union (EU) countries including Germany, Spain, Poland, Italy, and Hungary.

With 50 clinical trial sites open in the US, the company is currently enrolling participants for the Phase III trial.

The double-blind, randomised, placebo-controlled trial has been designed for assessing the tolerability, safety, and efficacy of buntanetap in early-stage PD patients.

In the trial, patients are being treated with 10mg and 20mg of buntanetap or a placebo, in addition to their standard of care, for six months.

The sites will enrol participants in the initial cohort of early PD patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

An interim analysis is expected in the second quarter of this year, if there is a sufficient number of participants who have received two months of therapy.

Annovis Bio founder, president, and CEO Maria Maccecchini said: “We are pleased to significantly expand our geographic reach with the addition of these EU sites that gives us the ability to efficiently enrol European patients in our study.”

The company stated that the interim analysis will be used for determining whether its original estimates for patient enrolment in the trial, of 150 patients in each arm, will be sufficient for observing a statistically significant treatment effect in the active arms and the control arm following six months of treatment.

It noted that the Phase III trial builds on the previous, proof-of-concept data obtained from the Phase IIa trial.

In the Phase IIa trial, buntanetap-treated patients demonstrated statistically significant improvements in motor function and coding speed, as measured by MDS-UPRDS Part III and WAIS Coding scores.